Gefjon Pharma
Building an outer membrane vesicle (OMV) platform to produce cost-effective vaccines and therapeutics, initially targeting E. coli infections in poultry to reduce antimicrobial use.
Gefjon Pharma has raised €1.3M across 1 funding round from 1 investor, most recently a round in Mar 2026. Based in Copenhagen, Denmark; active in Healthtech. Data as of 28 Oct 2026.
Copenhagen, Denmarkwww.gefjonpharma.com ↗
Total raised
€1.3M
€1,300,000
Funding rounds
1
Investors
1
distinct backers
Active since
2026-03
latest 2026-03
Funding by year
EUR raised per year · 2026 YTDGefjon Pharma — funding by year — interactive chart.
Data table
| Gefjon Pharma — funding by year | |
|---|---|
| 2026 | €1.3M |
Signals
High confidenceRaise-next likelihood30
base rate 30% for Other
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-03-03 | Other | €1.3M | BioInnovation Institute (BII) | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Oura Health€779MFinland · Healthtech
Global coverage: FundingData